MSA
AMRI

Mason Street Advisors’s Albany Molecular Research Inc AMRI Stock Holding History

Mason Street Advisors’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-5,505
Closed -$119K – 1528
2017
Q2 		$119K Buy
5,505
+290
+6% +$5.26K ﹤0.01% 1414
2017
Q1 		$73K Buy
5,215
+341
+7% +$5.58K ﹤0.01% 1474
2016
Q4 		$91K Buy
4,874
+285
+6% +$4.84K ﹤0.01% 1441
2016
Q3 		$76K Sell
4,589
-716
-13% -$10.6K ﹤0.01% 1437
2016
Q2 		$71K Buy
5,305
+509
+11% +$7.42K ﹤0.01% 1429
2016
Q1 		$73K Buy
4,796
+447
+10% +$7.01K ﹤0.01% 1395
2015
Q4 		$86K Buy
4,349
+379
+10% +$7.2K ﹤0.01% 1355
2015
Q3 		$69K Buy
3,970
+630
+19% +$12.8K ﹤0.01% 1373
2015
Q2 		$68K Buy
3,340
+179
+6% +$3.45K ﹤0.01% 1396
2015
Q1 		$56K Buy
3,161
+99
+3% +$1.69K ﹤0.01% 1429
2014
Q4 		$50K Buy
3,062
+114
+4% +$2.09K ﹤0.01% 1839
2014
Q3 		$65K Buy
2,948
+548
+23% +$11.2K ﹤0.01% 1779
2014
Q2 		$48K Buy
+2,400
New +$40.6K ﹤0.01% 1814

Other funds holding AMRI

AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Mason Street Advisors's AMRI Position: Q3 2017 in Review

Mason Street Advisors sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 5,505 shares — an estimated $119K sold.

Mason Street Advisors first reported a position in AMRI in Q2 2014 and held it in 13 quarters. The position peaked at $119K in Q2 2017. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.

  • Mason Street Advisors reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
  • Mason Street Advisors sold 5,505 Albany Molecular Research Inc shares in Q3 2017, an estimated $119K.
  • Mason Street Advisors first reported a position in Albany Molecular Research Inc in Q2 2014 and held it in 13 quarters.
  • Mason Street Advisors's Albany Molecular Research Inc position peaked at $119K in Q2 2017.
  • 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.

Based on Mason Street Advisors's 13F filing for Q3 2017, filed 13 Nov 2017.